
National Grand Rounds April 22, 2025 12:00 PM
National Grand Rounds
April 22, 2025
12:00-1:00 PM ET
Understanding FDA Warnings: Cardiac Risks of Lamotrigine and Safe Management Strategies for Clinicians
Join ACMT on Tuesday, April 22, 2025 at 12pm ET for a National Grand Rounds featuring Dr. David Auerbach as he addresses the FDA's safety advisory regarding lamotrigine and its potential cardiac effects. This important session, informed by research from the Ad Hoc ILAE/AES Task Force, will focus on lamotrigine's class IB antiarrhythmic properties and the associated risks for patients with certain cardiac conditions. Dr. Auerbach will outline the updated warnings added to the drug's label, offer practical guidelines for safe use, and discuss key considerations for healthcare providers managing patients on lamotrigine therapy.
Learning Objectives
- Identify the FDA safety warnings regarding the cardiac effects of lamotrigine and understand the specific patient populations at increased risk for proarrhythmic events.
- Apply updated clinical guidelines and practical strategies to safely manage lamotrigine therapy in patients, particularly those with pre-existing cardiac conditions, to minimize potential cardiac safety risks.
About The Series: ACMT's National Grand Rounds offer an in-depth and interactive platform for learning and discussion about issues that impact the research and practice of medical toxicology. Experts from within and outside medical toxicology will share their knowledge and experience and highlight areas for collaboration and mutual understanding.
Series Moderator: Nicholas Nacca, MD, Assistant Professor of Emergency Medicine, Director of Medical Toxicology, Associate Fellowship Director of Medical Toxicology Fellowship Program, University of Rochester Medical Center, Rochester, NY
This webinar is for ACMT members only.